Lyophilization Cycle Development for a High-Concentration Monoclonal Antibody Formulation Lacking a Crystalline Bulking Agent
Authors:
- James D. ColandeneJCJames D. Colandene
- Linda M. MaldonadoLMLinda M. Maldonado
- Alma T. CreaghACAlma T. Creagh
- John S. VrettosJVJohn S. Vrettos
- Kenneth G. GoadKGKenneth G. Goad
- Thomas M. SpitznagelTSThomas M. Spitznagel
- 1 June 2007
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 96 (6) , 1598-1608
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Design of Freeze-Drying Processes for Pharmaceuticals: Practical AdvicePharmaceutical Research, 2004
- Lyophilization Process Validation2004
- Annealing to optimize the primary drying rate, reduce freezing‐induced drying rate heterogeneity, and determine T'g in pharmaceutical lyophilizationJournal of Pharmaceutical Sciences, 2001
- Characterization of Murine Monoclonal Antibody to Tumor Necrosis Factor (TNF-MAb) Formulation for Freeze-Drying Cycle DevelopmentPharmaceutical Research, 2001
- Lyophilization and development of solid protein pharmaceuticalsInternational Journal of Pharmaceutics, 2000
- Application of infrared spectroscopy to development of stable lyophilized protein formulationsEuropean Journal of Pharmaceutics and Biopharmaceutics, 1998
- Characterization of the Sucrose/Glycine/ Water System by Differential Scanning Calorimetry and Freeze-Drying MicroscopyPharmaceutical Development and Technology, 1998
- Rational Design of Stable Lyophilized Protein Formulations: Some Practical AdvicePharmaceutical Research, 1997
- Determination of Soluble and Membrane Protein Structure by Fourier Transform Infrared Spectroscopy1994
- The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure☆International Journal of Pharmaceutics, 1990